Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus KENALOG 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus KENALOG 40.
KENALOG IN ORABASE vs KENALOG-40
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative properties; suppresses cytokine production, inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes lysosomal membranes.
Adjunctive treatment for inflammatory and ulcerative diseases of oral mucosa (e.g., aphthous ulcers, lichen planus)Topical corticosteroid for oral lesions
Allergic disorders (e.g., seasonal or perennial allergic rhinitis)Asthma (as prophylactic therapy)Atopic dermatitisContact dermatitisDrug hypersensitivity reactionsSystemic lupus erythematosusRheumatic disorders (e.g., rheumatoid arthritis, psoriatic arthritis)Dermatological conditions (e.g., pemphigus, severe erythema multiforme)Endocrine disorders (e.g., congenital adrenal hyperplasia, non-suppurative thyroiditis)Ophthalmic conditions (e.g., severe acute and chronic allergic and inflammatory processes)Neoplastic diseases (e.g., palliative management of leukemias and lymphomas)Nephrotic syndromeOrgan transplantation (adjunctive therapy)Ulcerative colitis (acute episodes)Sarcoidosis
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
Intra-articular injection: 10-40 mg for large joints, 5-15 mg for medium joints, 2.5-5 mg for small joints. Intralesional injection: 2.5-5 mg per lesion. Intramuscular injection: 40-80 mg once monthly. Not for IV or subcutaneous use.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
Terminal elimination half-life is approximately 2 to 3 hours after IV administration, but due to the triamcinolone acetonide suspension formulation, the effective half-life following intramuscular or intra-articular administration is prolonged to 2-3 weeks due to slow dissolution from the injection site.
Hepatic metabolism primarily via CYP3A4; undergoes reduction, oxidation, and conjugation.
Primarily hepatic via CYP3A4; undergoes reduction and conjugation to inactive metabolites.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Primarily hepatic metabolism followed by renal excretion of inactive metabolites. Less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 15-20% of total clearance.
Approximately 70-90% bound to corticosteroid-binding globulin and albumin.
68-80% bound to albumin and corticosteroid-binding globulin (transcortin).
Estimated Vd of 1.5-3.5 L/kg, reflecting extensive tissue distribution.
Approximately 1.4 L/kg. The large Vd indicates extensive tissue distribution, particularly into adipose tissue and muscle.
Systemic bioavailability via oral mucosa is low but not precisely quantified; local delivery is the primary route.
Intramuscular: 100% (by definition for IM); Intra-articular: 100% (local); Oral: not applicable (not available orally for systemic use; triamcinolone acetonide has low oral bioavailability due to first-pass metabolism).
No dose adjustment required for renal impairment.
No adjustment required for GFR >10 mL/min. In ESRD (GFR<10 mL/min), consider alternative therapy due to increased risk of fluid retention and hypertension.
No dose adjustment required for hepatic impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Use with caution; consider reduced dose of 25-50% of standard. Child-Pugh C: Avoid due to risk of severe side effects; alternative therapy recommended.
Safety and efficacy in pediatric patients have not been established; use only if clearly needed and use the smallest effective amount.
Not recommended for children under 1 year. For older children: 0.5-2 mg/kg intramuscularly every 1-4 weeks, up to max 60 mg. Intra-articular doses: 5-15 mg for large joints, 2.5-5 mg for medium joints. Intralesional: 1-2.5 mg per lesion.
Use the smallest effective amount for the shortest duration due to increased potential for systemic effects with age.
Use lowest effective dose due to increased risk of osteoporosis, glucose intolerance, and immunosuppression. Typical starting dose: 25-50% of adult dose; monitor closely for adverse effects.
No FDA black box warning.
Triamcinolone acetonide injectable suspension should not be administered intravenously. Systemic corticosteroids are not approved for epidural or intrathecal administration; serious neurologic events, including spinal cord infarction, paraplegia, and death, have been reported with such routes. Intramuscular administration of triamcinolone is not recommended for children under 2 years of age.
["Immunosuppression may increase susceptibility to infections","Adrenal suppression with prolonged use","Avoid use in patients with known hypersensitivity to corticosteroids","Use with caution in patients with diabetes, hypertension, or osteoporosis","Do not swallow or apply to large areas of skin"]
["Increased risk of infections; may mask signs of infection","Adrenal suppression particularly with high doses or prolonged use; taper slowly","Cushing's syndrome with prolonged use","Osteoporosis risk with long-term use","Gastrointestinal perforation especially in patients with inflammatory bowel disease or diverticulitis","Kaposi sarcoma reported in patients on corticosteroid therapy","Myopathy and muscle wasting","Ocular effects: cataracts, glaucoma, increased intraocular pressure","Behavioral and mood disturbances (e.g., euphoria, depression, psychosis)","Fluid and electrolyte disturbances (e.g., hypertension, hypokalemia)"]
["Systemic fungal infections","Hypersensitivity to triamcinolone or any component of the formulation","Viral or bacterial infections of the oral mucosa (e.g., herpes simplex)"]
["Systemic fungal infections","Hypersensitivity to triamcinolone or any component","Intrathecal or epidural administration","Intravenous administration","Idiopathic thrombocytopenic purpura (IM route)","Live or live-attenuated vaccines (concurrent use)"]
Data Pending Review
Data Pending Review
Avoid hot, spicy, or acidic foods during treatment as they may irritate the lesion. No specific food-drug interactions are known.
No specific food restrictions. However, corticosteroids can cause salt and water retention; patients with hypertension or heart failure should avoid high-sodium foods. May increase appetite and weight gain; advise balanced diet. Grapefruit juice may increase systemic exposure of some corticosteroids (though data limited for triamcinolone); caution with excessive grapefruit intake. Limit alcohol as it may increase risk of gastrointestinal bleeding.
Triamcinolone acetonide (KENALOG IN ORABASE) is a corticosteroid. Systemic absorption from oral mucosal application is minimal but may occur. In first trimester, corticosteroid use is associated with a small increased risk of oral clefts (odds ratio ~1.3-3.4). Second and third trimester use may cause fetal adrenal suppression, intrauterine growth restriction, and preterm birth if significant systemic exposure occurs. Topical use with minimal absorption is generally considered low risk, but theoretical risks persist.
Corticosteroids such as triamcinolone acetonide (Kenalog-40) are associated with an increased risk of orofacial clefts when administered during the first trimester. Use during pregnancy should be avoided unless the benefit clearly outweighs the risk. Second and third trimester exposure may increase the risk of fetal growth restriction, adrenal suppression, and preterm birth. The drug crosses the placenta and can cause fetal hypothalamic-pituitary-adrenal axis suppression.
Triamcinolone acetonide is excreted into human breast milk in low amounts following systemic administration. The milk-to-plasma ratio is unknown for topical oral formulation, but due to low systemic absorption, concentrations are expected to be negligible. No adverse effects on the infant have been reported with topical corticosteroids. Caution is advised with prolonged or extensive use.
Triamcinolone acetonide is excreted into human breast milk in small amounts; the milk-to-plasma ratio is not well defined for this formulation. Caution is advised as high doses may affect the infant's adrenal function or growth. Use only if clearly needed and monitor infant for signs of adrenal suppression.
No specific dose adjustment needed for standard use of KENALOG IN ORABASE during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) are not clinically relevant due to minimal systemic absorption. Avoid excessive application or use on large mucosal areas to minimize systemic exposure.
Pregnancy may alter pharmacokinetics of corticosteroids due to increased plasma volume, altered protein binding, and increased hepatic clearance; however, specific dose adjustments for Kenalog-40 are not established. Use the lowest effective dose for the shortest duration. Consider conversion to prednisone or other corticosteroids with more data on pregnancy dosing if prolonged treatment is required.
Category C
Category C
Apply a thin layer to the lesion after meals and at bedtime. Do not rub in; allow to form a film. Avoid use on infected lesions unless antifungal/antibacterial coverage is provided. Use with caution in patients with diabetes, hypertension, or peptic ulcer disease due to potential systemic absorption.
Kenalog-40 (triamcinolone acetonide injectable suspension) is a long-acting corticosteroid. Avoid intra-articular injection into unstable joints or joints with infection. Do not inject directly into tendons; risk of tendon rupture. Use caution in patients with diabetes mellitus (may increase blood glucose), tuberculosis, or ocular herpes simplex. Intra-articular injections may cause temporary flare of pain (post-injection flare) within 24-48 hours. Limit frequency of intra-articular injections to every 3-4 weeks. Do not use for epidural injection due to risk of rare but serious neurological events. Sterile technique mandatory to prevent iatrogenic infection.
Apply a thin layer to the affected area after meals and at bedtime.Do not rub or massage the paste into the tissue.Avoid eating or drinking immediately after application to allow the paste to adhere.Do not use if you have a fungal or bacterial infection in the mouth unless directed.Notify your doctor if symptoms persist beyond 7 days or if swelling occurs.
This medication is a corticosteroid that reduces inflammation and suppresses the immune system.Do not receive live vaccines while on this medication unless approved by your doctor.Report any signs of infection (fever, sore throat, pain at injection site) or sudden joint pain/swelling after injection.If you have diabetes, monitor blood glucose closely; this drug may increase blood sugar.Avoid abrupt discontinuation after long-term use; dose must be tapered under doctor's supervision.Protect skin from sun exposure; increased susceptibility to bruising and skin thinning.Inform all healthcare providers that you are receiving corticosteroid therapy.Do not drive or operate machinery if you experience dizziness or blurred vision after injection.